The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.

Dejan  Juric

Stock and Other Ownership Interests  - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics

Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Lilly; MapKure; Novartis; Pfizer; PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics

Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Scorpion Therapeutics; Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)

Kevin  Kalinsky

Employment - EQRx (I); GRAIL (I)

Stock and Other Ownership Interests  - EQRx (I); GRAIL (I)

Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda

Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)

Other Relationship - Genentech; Immunomedics

Nicholas C.  Turner

Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche

Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)

Komal L.  Jhaveri

Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology

Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical

Peter  Schmid

Employment - Roche (I)

Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics

Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)

Travel, Accommodations, Expenses - ESMO; SABS

Sherene  Loi

Honoraria - Mersana; MSD Oncology; Novartis; Roche/Genentech

Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - BMS

Other Relationship - Roche Medical writing support

Cristina  Saura

Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Phillips Health Works; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; MediTech; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; SeaGen; Synthon; Zymeworks

Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen

Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Novartis; Pfizer; Puma Biotechnology; Roche

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd'

Seock-Ah  Im

Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech

Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Other Relationship - Roche

Patrapim  Sunpaweravong

Honoraria - Amgen; AstraZeneca; BMS; Daiichi Sankyo; DKSH; Eisai; Janssen; Juniper Biologics; MSD; Novartis; Roche; Taiho Pharmaceutical; ZP Therapeutics

Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Daiichi Sankyo; Eisai; Janssen; MSD; Novartis; Roche; ZP Therapeutics

Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Exscientia (Inst); Janssen (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; BMS; DKSH; Eisai; Janssen; Juniper Biologics; MSD; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Zuellig Pharma

Huiping  Li

Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd

Antonino  Musolino

Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai Europe; Lilly; Seagen

Research Funding - Lilly; Roche (Inst)

Travel, Accommodations, Expenses - Pfizer

Qingyuan  Zhang

Research Funding - Roche (Inst)

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd

Zbigniew  Nowecki

Research Funding - Roche (Inst)

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd

Roland Ching-Yu  Leung

Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech

Eirini  Thanopoulou

Employment - Roche

Stock and Other Ownership Interests  - Roche

Patents, Royalties, Other Intellectual Property - Combination therapies for treatment of HER2 cancer

Noopur  Shankar

Employment - Genentech

Stock and Other Ownership Interests  - Roche/Genentech

Travel, Accommodations, Expenses - Genentech/Roche

Guiyuan  Lei

Employment - Roche

Stock and Other Ownership Interests  - Roche

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd

Jacob  Devine

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd

Thomas J  Stout

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd

Sibylle  Loibl

Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Menarini Group (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Menarini Group (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)

Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)